Sachanandani Neil S, Piccirillo Jay F, Kramper Maggie A, Thawley Stanley E, Vlahiotis Anna
Division of Clinical Outcomes Research, Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri 63110, USA.
Arch Otolaryngol Head Neck Surg. 2009 Mar;135(3):303-7. doi: 10.1001/archoto.2008.555.
To evaluate whether nasal administration of budesonide in adults with chronic rhinosinusitis for 30 days suppresses adrenal function and to assess its clinical efficacy.
An open-label prospective study.
Academic medical center.
We assessed adrenal function in 9 patients using the cosyntropin test before and after budesonide therapy.
Budesonide respule therapy.
Scores from the Sino-Nasal Outcome Test-20 (SNOT-20), a tool for assessing rhinosinusitis health and quality of life, were used to assess efficacy of budesonide treatment.
All of our patients showed adequate adrenal response to cosyntropin stimulation before and after the budesonide trial. The mean difference in SNOT-20 scores was -1 (95% confidence interval, -1.77 to -0.23; P = .02), indicating clinically significant improvement after therapy.
Our findings suggest that using budesonide nasal wash may be clinically effective in decreasing the symptoms of chronic rhinosinusitis and does so without suppression of the hypothalamic-pituitary-adrenal axis in patients with chronic rhinosinusitis.
评估布地奈德鼻腔给药30天对成年慢性鼻窦炎患者肾上腺功能的抑制作用,并评估其临床疗效。
开放标签前瞻性研究。
学术医疗中心。
我们在布地奈德治疗前后,使用促肾上腺皮质激素试验评估了9例患者的肾上腺功能。
布地奈德混悬液治疗。
使用鼻鼻窦结局测试-20(SNOT-20)评分,这是一种评估鼻窦炎健康状况和生活质量的工具,用于评估布地奈德治疗的疗效。
在布地奈德试验前后,所有患者对促肾上腺皮质激素刺激均显示出足够的肾上腺反应。SNOT-20评分的平均差异为-1(95%置信区间,-1.77至-0.23;P = 0.02),表明治疗后有临床显著改善。
我们的研究结果表明,使用布地奈德鼻腔冲洗可能在临床上有效减轻慢性鼻窦炎的症状,并且不会抑制慢性鼻窦炎患者的下丘脑-垂体-肾上腺轴。